Streetbeat News

Price Targets

FOUR

Wells Fargo analyst Andrew Bauch has initiated coverage on Shift4 Payments (NYSE:FOUR) with an Overweight rating and a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:37 am

TOST

Wells Fargo analyst Jeff Cantwell has initiated coverage on Toast (NYSE:TOST) with an Underweight rating and a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:34 am

SHOP

Wells Fargo analyst Andrew Bauch has initiated coverage on Shopify (NYSE:SHOP) with an Overweight rating and a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:29 am

ON

Needham analyst Quinn Bolton has maintained a 'Buy' rating on ON Semiconductor (NASDAQ:ON) but lowered the price target from $120 to $92.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:22 am

CHGG

Piper Sandler analyst Arvind Ramnani has maintained a Neutral rating on Chegg (NYSE:CHGG) and lowered the price target from $13 to $9.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:18 am

ZI

Piper Sandler analyst Brent Bracelin maintains an Overweight rating on ZoomInfo Technologies (NASDAQ:ZI) but lowers the price target from $21 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:11 am

EXP

Raymond James analyst Patrick Tyler Brown has maintained an Outperform rating on Eagle Materials (NYSE:EXP) but lowered the price target from $193 to $170.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:09 am

LITE

Raymond James analyst Simon Leopold has maintained an 'Outperform' rating on Lumentum Holdings (NASDAQ:LITE) but lowered the price target from $51.5 to $49.5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:03 am

RIOT

Bernstein analyst Gautam Chhugani has initiated coverage on Riot Platforms (NASDAQ:RIOT) with an Outperform rating and a price target of $15.6.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 8:25 pm

VRDN

Needham analyst Serge Belanger has maintained a 'Buy' rating on Viridian Therapeutics (NASDAQ:VRDN), but lowered the price target from $40 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 7:17 pm